Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

OLMA

+ Watchlist+ Portfolio

Olema Pharmaceuticals, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.22
52-Week Range
$6.24 – $36.26
Market Cap
$618.50M
P/E (TTM)
—
EPS (TTM)
-2.40
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.68
PEG Ratio
—
Return on Equity
-69.77%
Return on Assets
-39.82%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
6.12
Debt/Equity
0.01
Total Debt
$3.36M
Free Cash Flow
$-95.10M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$208.09M

Market Snapshot

About

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for estrogen receptor-positive breast cancer. The company focuses on endocrine therapies designed to overcome resistance mechanisms in HR+ breast cancer. Olema's lead candidate is palazestrant, a complete estrogen receptor antagonist in clinical trials.